UY32038A - Inmunoblobulinas anti-cd127 y sus usos - Google Patents
Inmunoblobulinas anti-cd127 y sus usosInfo
- Publication number
- UY32038A UY32038A UY0001032038A UY32038A UY32038A UY 32038 A UY32038 A UY 32038A UY 0001032038 A UY0001032038 A UY 0001032038A UY 32038 A UY32038 A UY 32038A UY 32038 A UY32038 A UY 32038A
- Authority
- UY
- Uruguay
- Prior art keywords
- immunoblobulinas
- biological activity
- multiple sclerosis
- treating multiple
- binding proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Nuevos procedimientos de tratamiento de la esclerosis múltiple y otras enfermedades autoinmunitarias o trastornos inflamatorios, y antagonistas, que incluyen proteínas de unión aisladas para su uso en los nuevos procedimientos. Se proporciona un procedimiento de tratamiento de la esclerosis múltiple que comprende la neutralización de la actividad biológica de la IL7 mediante la unión a CD127 o IL-7. Las proteínas de la unión aisladas también pueden neutralizar la actividad biológica de la TSLP
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8729408P | 2008-08-08 | 2008-08-08 | |
US16980109P | 2009-04-16 | 2009-04-16 | |
US21862709P | 2009-06-19 | 2009-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY32038A true UY32038A (es) | 2010-03-26 |
Family
ID=41382165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001032038A UY32038A (es) | 2008-08-08 | 2009-08-06 | Inmunoblobulinas anti-cd127 y sus usos |
Country Status (23)
Country | Link |
---|---|
US (2) | US20110287000A1 (es) |
EP (1) | EP2318442A1 (es) |
JP (1) | JP2011530533A (es) |
KR (1) | KR20110044777A (es) |
CN (1) | CN102177179A (es) |
AR (1) | AR072985A1 (es) |
AU (1) | AU2009279471A1 (es) |
BR (1) | BRPI0916945A2 (es) |
CA (1) | CA2733432A1 (es) |
CL (1) | CL2011000269A1 (es) |
CO (1) | CO6341640A2 (es) |
CR (1) | CR20110118A (es) |
DO (1) | DOP2011000041A (es) |
EA (1) | EA201100150A1 (es) |
IL (1) | IL211034A0 (es) |
MA (1) | MA32621B1 (es) |
MX (1) | MX2011001477A (es) |
NZ (1) | NZ590994A (es) |
PE (1) | PE20110382A1 (es) |
TW (1) | TW201018482A (es) |
UY (1) | UY32038A (es) |
WO (1) | WO2010017468A1 (es) |
ZA (1) | ZA201100974B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8171134B2 (en) * | 2009-03-18 | 2012-05-01 | At&T Intellectual Property I, L.P. | Methods and apparatus to characterize and predict network health status |
KR20130028055A (ko) | 2010-01-28 | 2013-03-18 | 글락소 그룹 리미티드 | Cd 127 결합 단백질 |
US20130046015A1 (en) * | 2010-02-11 | 2013-02-21 | Robert C. Axtell | Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease |
AR080291A1 (es) * | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | Anticuerpos antagonistas anti receptor de il-7 y procedimientos |
AU2014201648B2 (en) * | 2010-02-24 | 2016-05-12 | Rinat Neuroscience Corp. | Antagonist anti-il-7 receptor antibodies and methods |
CA2801509A1 (en) | 2010-06-02 | 2011-12-08 | Dainippon Sumitomo Pharma Co., Ltd. | Treatment drug for autoimmune diseases and allergic diseases |
WO2012021165A2 (en) * | 2010-08-10 | 2012-02-16 | The Scripps Research Institute | Methods and compositions for treating disorders associated with hyperactive immune system |
EP3252076B1 (en) | 2011-01-14 | 2019-09-04 | The Regents Of The University Of California | Diagnostic use of antibodies against ror-1 protein |
EP2583980A1 (en) | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
FR2988479B1 (fr) * | 2012-03-23 | 2014-12-19 | Hospices Civils Lyon | Procede de determination de la susceptibilite aux infections nosocomiales |
GB2535937B (en) * | 2014-04-29 | 2017-05-31 | Bio-Cancer Treat Int Ltd | Arginase I for treating rheumatoid arthritis |
EP2955196A1 (en) | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
JP2017534577A (ja) * | 2014-09-15 | 2017-11-24 | ジェネンテック, インコーポレイテッド | Pd−1軸結合拮抗薬及びil−17結合拮抗薬を使用したがんの治療方法 |
EP3207061A1 (en) | 2014-10-18 | 2017-08-23 | Pfizer Inc | Anti-il-7r antibody compositions |
WO2016142426A1 (en) * | 2015-03-11 | 2016-09-15 | Glaxosmithkline Intellectual Property Development Limited | Tslp binding proteins |
WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
AU2016335750B2 (en) | 2015-10-07 | 2023-05-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia |
BR112018067479A2 (pt) | 2016-02-29 | 2019-01-15 | Ose Immunotherapeutics | anticorpo, fragmento de ligação ao antígeno de um anticorpo, molécula quimérica, receptor de antígeno quimérico, polinucleotídeo, célula, métodos para preparação de receptor de antígeno quimérico, para fabricação de um anticorpo e para determinação da presença de células cd127+, composição farmacêutica, meio terapêutico de combinação, método de diagnóstico, e, uso de um anticorpo anti-cd127 ou um fragmento de ligação ao antígeno do mesmo |
RU2769352C2 (ru) | 2016-12-09 | 2022-03-30 | Осе Иммьюнотерапьютикс | Антитела и полипептиды, направленные против cd127 |
JOP20190243A1 (ar) | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
BR112021014106A2 (pt) * | 2019-01-22 | 2021-10-13 | Bristol-Myers Squibb Company | Anticorpos contra subunidade alfa de il-7r e usos dos mesmos |
CN117343173A (zh) * | 2019-03-07 | 2024-01-05 | 瑞阳(苏州)生物科技有限公司 | 人IL-1β蛋白结合分子及其编码基因和应用 |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
CN115279404A (zh) | 2020-02-13 | 2022-11-01 | 安进公司 | 人抗tslp抗体的配制品及治疗炎性疾病的方法 |
US20230073888A1 (en) | 2020-02-13 | 2023-03-09 | Amgen Inc. | Treatment of atopic dermatitis with anti-tslp antibody |
JP2023513833A (ja) | 2020-02-18 | 2023-04-03 | アムジェン インコーポレイテッド | ヒト抗tslp抗体の製剤及びそれを使用する方法 |
MX2023006294A (es) | 2020-12-02 | 2023-06-13 | Glaxosmithkline Ip Dev Ltd | Proteinas de union a il-7 y su uso en tratamientos medicos. |
WO2023227641A1 (en) | 2022-05-27 | 2023-11-30 | Glaxosmithkline Intellectual Property Development Limited | Use of tnf-alpha binding proteins and il-7 binding proteins in medical treatment |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194375A (en) * | 1989-06-15 | 1993-03-16 | Immunex Corporation | Dna encoding interleukin-7 receptors and methods of use |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1994028160A1 (fr) * | 1993-06-01 | 1994-12-08 | Toray Industries, Inc. | Anticorps monoclonal, procede de production, et utilisation |
US20050054054A1 (en) * | 2002-11-12 | 2005-03-10 | Foss Francine M. | Interleukin-7 molecules with altered biological properties |
WO2005123774A2 (en) * | 2004-06-15 | 2005-12-29 | Erol Fikrig | Antibodies to west nile virus polypeptides |
WO2006052660A2 (en) * | 2004-11-04 | 2006-05-18 | Childrens Hospital Los Angeles Research Institute | Il-7 receptor blockade to suppress immunity |
PE20061391A1 (es) * | 2005-02-14 | 2007-01-09 | Wyeth Corp | Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il-17f |
CA2513350A1 (en) * | 2005-03-02 | 2006-09-02 | Sydney West Area Health Service | Treatment for multiple sclerosis |
GB2434578A (en) * | 2006-01-26 | 2007-08-01 | Univ Basel | Transgenic animals |
-
2009
- 2009-08-06 UY UY0001032038A patent/UY32038A/es unknown
- 2009-08-06 TW TW098126600A patent/TW201018482A/zh unknown
- 2009-08-07 NZ NZ590994A patent/NZ590994A/xx not_active IP Right Cessation
- 2009-08-07 KR KR1020117005442A patent/KR20110044777A/ko not_active Application Discontinuation
- 2009-08-07 CN CN2009801397595A patent/CN102177179A/zh not_active Withdrawn
- 2009-08-07 US US13/057,893 patent/US20110287000A1/en not_active Abandoned
- 2009-08-07 AU AU2009279471A patent/AU2009279471A1/en not_active Abandoned
- 2009-08-07 US US12/537,705 patent/US20100040616A1/en not_active Abandoned
- 2009-08-07 CA CA2733432A patent/CA2733432A1/en not_active Abandoned
- 2009-08-07 JP JP2011522273A patent/JP2011530533A/ja not_active Withdrawn
- 2009-08-07 EP EP09791287A patent/EP2318442A1/en not_active Withdrawn
- 2009-08-07 WO PCT/US2009/053136 patent/WO2010017468A1/en active Application Filing
- 2009-08-07 AR ARP090103039A patent/AR072985A1/es unknown
- 2009-08-07 MX MX2011001477A patent/MX2011001477A/es unknown
- 2009-08-07 EA EA201100150A patent/EA201100150A1/ru unknown
- 2009-08-07 PE PE2011000140A patent/PE20110382A1/es not_active Application Discontinuation
- 2009-08-07 BR BRPI0916945A patent/BRPI0916945A2/pt not_active IP Right Cessation
-
2011
- 2011-02-02 DO DO2011000041A patent/DOP2011000041A/es unknown
- 2011-02-03 IL IL211034A patent/IL211034A0/en unknown
- 2011-02-07 ZA ZA2011/00974A patent/ZA201100974B/en unknown
- 2011-02-08 CL CL2011000269A patent/CL2011000269A1/es unknown
- 2011-02-11 CO CO11016609A patent/CO6341640A2/es unknown
- 2011-03-03 CR CR20110118A patent/CR20110118A/es not_active Application Discontinuation
- 2011-03-08 MA MA33682A patent/MA32621B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
CO6341640A2 (es) | 2011-11-21 |
MA32621B1 (fr) | 2011-09-01 |
CN102177179A (zh) | 2011-09-07 |
AU2009279471A1 (en) | 2010-02-11 |
TW201018482A (en) | 2010-05-16 |
EP2318442A1 (en) | 2011-05-11 |
CR20110118A (es) | 2011-07-28 |
NZ590994A (en) | 2012-09-28 |
IL211034A0 (en) | 2011-04-28 |
CL2011000269A1 (es) | 2012-07-20 |
MX2011001477A (es) | 2011-03-25 |
US20100040616A1 (en) | 2010-02-18 |
JP2011530533A (ja) | 2011-12-22 |
AR072985A1 (es) | 2010-10-06 |
DOP2011000041A (es) | 2011-02-28 |
KR20110044777A (ko) | 2011-04-29 |
US20110287000A1 (en) | 2011-11-24 |
CA2733432A1 (en) | 2010-02-11 |
EA201100150A1 (ru) | 2011-10-31 |
BRPI0916945A2 (pt) | 2015-11-24 |
PE20110382A1 (es) | 2011-06-27 |
WO2010017468A1 (en) | 2010-02-11 |
ZA201100974B (en) | 2012-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY32038A (es) | Inmunoblobulinas anti-cd127 y sus usos | |
BRPI1013771A2 (pt) | "células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores." | |
CR20120490A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
CR20120248A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
CL2014003110A1 (es) | Anticuerpo anti-fcrn; secuencias que lo codifican; vector; célula huésped; proceso de producción; composición farmacéutica que lo comprende; uso para el tratamiento de enfermedad autoinmune; y ensayo para probar la capacidad de un anticuerpo para bloquear la actividad de fcrn humano. | |
UY32808A (es) | Inmunoglobulinas como dominio variable dual y usos de las mismas | |
ECSP077280A (es) | Moduladores de quinasa de pirrolo-piridina | |
UY30732A1 (es) | Compuestos para la modulacion de la actividad del c-fms y/o el c-kit y sus usos aplicables | |
CR20130374A (es) | Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos | |
HN2008001292A (es) | Anticuerpos contra la ii -22 humana y usos para los mismos | |
CO6531489A2 (es) | Anticuerpo anti -tslp modificado por técnicas de ingenieria genética | |
UY35427A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
ECSP13012402A (es) | Inmunoglobulinas con dominio variable dual y su uso | |
UY35425A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
CR20120154A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
BRPI0909817A2 (pt) | uso de células-tronco mesenquimais para tratamento de doenças e distúrbios genéticos | |
UY35426A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
UY31904A (es) | Anticuerpos contra il-6 y sus usos | |
UY32060A (es) | Anticuerpos anti-il-13 obtenidos mediante ingeniería, composiciones , métodos y usos | |
CO6592067A2 (es) | Proteinas de elance a cd 127 | |
ECSP099296A (es) | Inmuno-reguladores, preparaciones y composiciones que incluyen los inmuno-reguladores, pruebas para evaluar la actividad de los inmuno-reguladores y preparaciones y composiciones que incluyen los mismos y métodos | |
ECSP13012673A (es) | Métodos y composiciones para inmunoterapia para enfermedad neural | |
ECSP13012536A (es) | Composiciones de anticuerpo y métodos de uso | |
CL2012003624A1 (es) | Uso estético de acido cicórico y sus derivados para regular la pigmentacion de la piel; kit para tratar y/o prevenir trastornos de pigmentacion de la piel y/o imperfecciones de la piel. | |
UY33662A (es) | Combinaciones que comprenden inhibidores de dhodh e inhibidores de cox |